School of Cardiovascular & Metabolic Health

Mr Ryan McChrystal

  • Research Assistant (Cardiovascular & Metabolic Health)

Biography

Ryan McChrystal is an early career researcher based in the School of Health and Wellbeing. Ryan is currently working as a research assistant under a Wellcome-funded project (301005/Z/23/Z) awarded to Dr Jennifer Lees. This project is exploring kidney function as a modulator of treatment in cancer patients and involves access to a substantial volume of cancer trial IPD, exploring the use of kidney function (eGFR slope) as an indicator of treatment outcomes. Ryan is also a member of the NIHR-MRC Trial Methodology Research Partnership and was a doctoral student in the TMRP doctoral training programme.

Ryan completed his PhD in 2026, in which he developed risk prediction models for attrition in newer glucose-lowering drug trials and contributed extensively to the attrition literature base. In 2023, Ryan completed an integrated Master's degree in Biological Sciences at Queen's university while working as a clinical research assistant at the Northern Ireland Clinical Research Facility. Here, Ryan worked extensively on the planning, analysis and interpretation of results for substudies and projects associated with clinical trials in bronchiectasis.

Research interests

Ryan's research interests involve leveraging existing clinical data, particularly individual participant data, to answer clinically important questions and find methods that improve the design, conduct, and analysis of clinical trials. Ryan has extensive experience in statistical analysis and data analytics in R, as well as building Bayesian models in Stan.

Publications

List by: Type | Date

Jump to: 2025
Number of items: 5.

2025

Hanlon, P. et al. (2025) Assessing the representativeness of trials of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database. BMC Medicine, 23(1), 661. (doi: 10.1186/s12916-025-04492-2) (PMID:41299446) (PMCID:PMC12659586)

McChrystal, Ryan ORCID logoORCID: https://orcid.org/0000-0003-1513-6966, Hanlon, Peter ORCID logoORCID: https://orcid.org/0000-0002-5828-3934, Lees, Jennifer S. ORCID logoORCID: https://orcid.org/0000-0001-6331-0178, Phillippo, David M., Welton, Nicky J., Gillies, Katie and McAllister, David ORCID logoORCID: https://orcid.org/0000-0003-3550-1764 (2025) Modelling rates of trial attrition: an analysis of individual participant data from 90 randomized controlled trials of pharmacological interventions for multiple conditions. Journal of Clinical Epidemiology, 187, 111971. (doi: 10.1016/j.jclinepi.2025.111971) (PMID:40921288)

Wightman, H. et al. (2025) Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Medicine, 22(4), e1004553. (doi: 10.1371/journal.pmed.1004553) (PMID:40193407)

Hanlon, P. et al. (2025) Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis. JAMA: Journal of the American Medical Association, 333(12), pp. 1062-1073. (doi: 10.1001/jama.2024.27402) (PMID:39899304) (PMCID:PMC11791772)

McChrystal, Ryan ORCID logoORCID: https://orcid.org/0000-0003-1513-6966, Lees, Jennifer ORCID logoORCID: https://orcid.org/0000-0001-6331-0178, Gillies, Katie, McAllister, David ORCID logoORCID: https://orcid.org/0000-0003-3550-1764 and Hanlon, Peter ORCID logoORCID: https://orcid.org/0000-0002-5828-3934 (2025) Participant and trial characteristics reported in predictive analyses of trial attrition: an umbrella review of systematic reviews of randomised controlled trials across multiple conditions. Trials, 26, 84. (doi: 10.1186/s13063-025-08794-x) (PMID:40075486)

This list was generated on Thu Nov 19 02:10:13 2026 GMT.
Jump to: Articles
Number of items: 5.

Articles

Hanlon, P. et al. (2025) Assessing the representativeness of trials of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database. BMC Medicine, 23(1), 661. (doi: 10.1186/s12916-025-04492-2) (PMID:41299446) (PMCID:PMC12659586)

McChrystal, Ryan ORCID logoORCID: https://orcid.org/0000-0003-1513-6966, Hanlon, Peter ORCID logoORCID: https://orcid.org/0000-0002-5828-3934, Lees, Jennifer S. ORCID logoORCID: https://orcid.org/0000-0001-6331-0178, Phillippo, David M., Welton, Nicky J., Gillies, Katie and McAllister, David ORCID logoORCID: https://orcid.org/0000-0003-3550-1764 (2025) Modelling rates of trial attrition: an analysis of individual participant data from 90 randomized controlled trials of pharmacological interventions for multiple conditions. Journal of Clinical Epidemiology, 187, 111971. (doi: 10.1016/j.jclinepi.2025.111971) (PMID:40921288)

Wightman, H. et al. (2025) Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Medicine, 22(4), e1004553. (doi: 10.1371/journal.pmed.1004553) (PMID:40193407)

Hanlon, P. et al. (2025) Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis. JAMA: Journal of the American Medical Association, 333(12), pp. 1062-1073. (doi: 10.1001/jama.2024.27402) (PMID:39899304) (PMCID:PMC11791772)

McChrystal, Ryan ORCID logoORCID: https://orcid.org/0000-0003-1513-6966, Lees, Jennifer ORCID logoORCID: https://orcid.org/0000-0001-6331-0178, Gillies, Katie, McAllister, David ORCID logoORCID: https://orcid.org/0000-0003-3550-1764 and Hanlon, Peter ORCID logoORCID: https://orcid.org/0000-0002-5828-3934 (2025) Participant and trial characteristics reported in predictive analyses of trial attrition: an umbrella review of systematic reviews of randomised controlled trials across multiple conditions. Trials, 26, 84. (doi: 10.1186/s13063-025-08794-x) (PMID:40075486)

This list was generated on Thu Nov 19 02:10:13 2026 GMT.